
    
      To test the ability of a daily 3-month treatment with triheptanoin to prevent migraine
      attacks in 10 migraine patients.

      This is an open, non-randomized pilot trial that might justify a placebo-controlled trial, if
      there are at least 50% of patients with â‰¥50% reduction in attack frequency.
    
  